Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1027-1034

  Zhu, Kexiu ^a   Chen, Lihong ^b   Han, Xiaobing ^a   Wang, Jia ^a   Wang, Jue ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Cervical cancer; Cisplatin; Drug resistance; MDR1 P gp; Twist1

Indexed keywords

CISPLATIN; MULTIDRUG RESISTANCE PROTEIN 1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL ACTIVITY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; NUCLEAR PROTEINS; P-GLYCOPROTEIN; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TWIST TRANSCRIPTION FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 84863033587     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1633     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Greven K, Petereit D, Vermorken JB and Lanciano R: Current developments in the treatment of newly diagnosed cervical cancer. Hematol Oncol Clin North Am 13: 275-303, 1999. (Pubitemid 29104719)
3. Cornelio DB, Roesler R and Schwartsmann G: Emerging therapeutic agents for cervical cancer. Recent Pat Anticancer Drug Discov 4: 196-206, 2009.
4. Sardi JE, Boixadera MA and Sardi JJ: Neoadjuvant chemotherapy in cervical cancer: a new trend. Curr Opin Obstet Gynecol 17: 43-47, 2005. (Pubitemid 40315263)
5. Moore DH: Neoadjuvant chemotherapy for cervical cancer. Expert Opin Pharmacother 4: 859-867, 2003.
6. Tao X, Hu W, Ramirez PT and Kavanagh JJ: Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 110: S67-S71, 2008.
7. Brabec V and Kasparkova J: Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 5: 147-161, 2002. (Pubitemid 35033806)
8. Djeu JY and Wei S: Clusterin and chemoresistance. Adv Cancer Res 105: 77-92, 2009.
9. Konishi I, Nanbu K and Mandai M, et al: Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol Oncol 70: 365-371, 1998. (Pubitemid 28473636)
10. Britten RA, Liu D, Tessier A, Hutchison MJ and Murray D: ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89: 453-457, 2000.
11. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286, 2006.
12. Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7: 813-821, 2006.
13. Xia Z, Zhu Z and Zhang L, et al: Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol Rep 20: 1433-1439, 2008.
14. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007. (Pubitemid 46809165)
15. Yang J, Mani SA and Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004. (Pubitemid 38798858)
16. Iseri OD, Kars MD, Arpaci F, Atalay C, Pak I and Gunduz U: Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45, 2011.
17. Yang AD, Fan F and Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
18. Wang X, Ling MT and Guan XY, et al: Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23: 474-482, 2004. (Pubitemid 38175002)
19. Li QQ, Xu JD and Wang WJ, et al: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657-2665, 2009.
20. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67: 1979-1987, 2007. (Pubitemid 46424214)
21. Shibata K, Kajiyama H and Ino K, et al: Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 19: 81-85, 2008.
22. Kwok WK, Ling MT and Lee TW, et al: Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65: 5153-5162, 2005. (Pubitemid 40827324)
23. Martin TA, Goyal A, Watkins G and Jiang WG: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 12: 488-496, 2005. (Pubitemid 40884264)
24. Yan-Qi Z, Xue-Yan G and Shuang H, et al: Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer. Pathology 39: 470-475, 2007. (Pubitemid 47450590)
25. Puisieux A, Valsesia-Wittmann S and Ansieau S: A twist for survival and cancer progression. Br J Cancer 94: 13-17, 2006. (Pubitemid 43088534)
26. Chen T: Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev 62: 1257-1264, 2010.
27. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394, 2002. (Pubitemid 34651384)
28. Sampath J, Sun D and Kidd VJ, et al: Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367, 2001.
29. El-Osta A, Kantharidis P, Zalcberg JR and Wolffe AP: Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 22: 1844-1857, 2002. (Pubitemid 34175000)
30. Gomez-Martinez A, Garcia-Morales P and Carrato A, et al: Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res 5: 641-653, 2007. (Pubitemid 46985052)
31. Chen Y, Tang Y, Wang MT, Zeng S and Nie D: Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 67: 10361-10367, 2007. (Pubitemid 350070811)
32. Yang MH, Wu MZ and Chiou SH, et al: Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295-305, 2008.
33. Ding Z, Yang L and Xie X, et al: Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136: 1697-1707, 2010.